Theriva Biologics (TOVX) Current Deferred Revenue (2015 - 2023)
Theriva Biologics (TOVX) posted quarterly Current Deferred Revenue of $906000.0 for Q4 2023, up 72.57% quarter-over-quarter from $525000.0 in Q3 2023.
Theriva Biologics (TOVX) Current Deferred Revenue (2015 - 2023) Analysis & Trends
Theriva Biologics (TOVX) has reported Current Deferred Revenue for 5 consecutive years, with $906000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Current Deferred Revenue changed N/A year-over-year to $906000.0; the TTM figure through Dec 2023 stood at $906000.0 (changed N/A YoY), while the FY2023 annual figure was $906000.0, changed N/A from the prior year.
- Current Deferred Revenue advanced to $906000.0 in Q4 2023 per TOVX's latest filing, from $525000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $906000.0 in Q4 2023 and bottomed at $525000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 906,000.00 |
| Sep 30, 2023 | 525,000.00 |
| Dec 31, 2018 | 99,000.00 |
| Sep 30, 2018 | 97,000.00 |
| Jun 30, 2018 | 95,000.00 |
| Mar 31, 2018 | 92,000.00 |
| Dec 31, 2017 | 90,000.00 |
| Sep 30, 2017 | 88,000.00 |
| Jun 30, 2017 | 75,000.00 |
| Mar 31, 2017 | 40,000.00 |
| Dec 31, 2016 | 3,000.00 |
| Sep 30, 2016 | 51,000.00 |
| Jun 30, 2016 | 50,000.00 |
| Mar 31, 2016 | 49,000.00 |
| Dec 31, 2015 | 21,000.00 |
| Sep 30, 2015 | 55,000.00 |